Sesen Bio, Inc.

Informe acción NasdaqCM:SESN

Capitalización de mercado: US$2.6b

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Sesen Bio Dirección

Dirección controles de criterios 3/4

Información clave

Thomas Cannell

Chief Executive Officer (CEO)

US$4.9m

Compensación total

Porcentaje del salario del CEO11.34%
Permanencia del CEO4.6yrs
Participación del CEO0.05%
Permanencia media de la dirección3.6yrs
Promedio de permanencia en la Junta Directiva3.1yrs

Actualizaciones recientes de la dirección

Recent updates

Seeking Alpha • Sep 21

Sesen Bio and Carisma Therapeutics announce merger agreement

Sesen Bio (NASDAQ:SESN) and Carisma Therapeutics has entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on the advancement of Carisma’s proprietary cell therapy platform that utilizes engineered macrophages and monocytes to potentially transform the treatment of cancer and other serious disorders. The combined company expected to have ~$180M of cash, equivalents and marketable securities at close, including $30M from a concurrent financing by Carisma, which is expected to fund the combined company through 2024. Also, the cash runway of combined company expected to enable multiple clinical readouts across Carisma programs. The combined company is expected to operate under the name Carisma Therapeutics and trade on Nasdaq under the ticker symbol “CARM”.
Seeking Alpha • Aug 08

Sesen Bio GAAP EPS of -$0.16 misses by $0.03

Sesen Bio press release (NASDAQ:SESN): Q2 GAAP EPS of -$0.16 misses by $0.03. Company continues to assess potential strategic alternatives with the goal of maximizing shareholder value. Cash, cash equivalents and marketable securities were $161.2 million as of June 30, 2022, compared to $151.1 million as of June 30, 2021. Shares -1.82% PM.
Seeking Alpha • Jul 27

Sesen Bio granted additional time period for regaining compliance

Nasdaq Listing Qualifications department notified Sesen Bio (NASDAQ:SESN) that it has been granted a second 180-day grace period, or until Jan.23, 2023 for regaining compliance with the minimum bid price requirement. In January, the company had received its non-compliance letter and was granted time until July 25, 2022, to regain compliance with the minimum bid price requirement. The stock will be transferred to the Nasdaq Capital Market effective July 28, 2022 and will continue to trade under the current symbol. Shares trading 2% down premarket
Seeking Alpha • Jul 18

Sesen Bio slips after decision to pause U.S. studies for lead asset

The shares of cancer-focused biotech Sesen Bio (NASDAQ:SESN) traded lower in the pre-market Monday after the company announced its decision to pause further development of its lead asset Vicineum in the U.S. Sesen (SESN) noted that after discussions with the FDA, the company reassessed the development path for Vicineum, including a Phase 3 trial for the treatment in non-muscle invasive bladder cancer (NMIBC). The decision to pause further studies allows the company to save cash as it explores potential strategic alternatives to maximize shareholder value, according to the management. Additionally, Sesen (SESN) expects to form a partnership for the further development of Vicineum. However, the company’s Chief Executive, Dr. Thomas Cannell, noted that the current commercial environment of NMIBC also led to its decision. “We have also recently observed an evolution of the current treatment paradigm in NMIBC, with substantial uptake of intravesical chemotherapy (monotherapy and combination therapy) during the ongoing BCG shortage,” he said. In Aug. 2021, the FDA declined to approve Vicineum for the treatment of BCG-unresponsive NMIBC.
Seeking Alpha • Jun 02

Sesen Bio: Another Net-Net Biopharma Exploring Strategic Alternatives

SESN is a clinical-stage biopharma company working on the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). FDA declined to approve the company's flagship drug Vicineum. Subsequently, management has started a strategic review. SESN trades at $0.58/share vs $0.75/share of net cash.
Artículo de análisis • Apr 17

We Think Sesen Bio (NASDAQ:SESN) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Artículo de análisis • Dec 05

We're Keeping An Eye On Sesen Bio's (NASDAQ:SESN) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Seeking Alpha • Nov 24

Sesen Bio: Interesting Price Drop After CRL

Sesen received a CRL in August. Another trial will be needed. Sesen held a Type A meeting with the FDA on Oct. 29 on the CMC questions.
Seeking Alpha • Nov 17

Sesen Bio: Hoping For An Easy Revalidation Of Vicineum By 2022

The US FDA published the warning letter on October 27, 2021, just 2 days before CMC Type A meeting with Sesen Bio. The move informed its rejection of the BLA. Ahead of the Type A meeting, the burden of proof will be on Sesen’s side to show the efficacy of Vicineum post-2017. Sesen Bio is gearing towards product commercialization with strategic hires into 2022. Study shows that high-prescribing urologists would use a treatment agent branded with Vicineum in more than 80% of the BCG-unresponsive NMIBC patients as opposed to 17% with Keytruda. Sesen Bio is able to fund its capital operations including R&D until 2023 when it is expected to begin commercialization of Vicineum.
Seeking Alpha • Aug 23

Sesen Bio: The Road Ahead

The current FDA environment is under heavy scrutiny with much uncertainty. Sesen Bio's lead drug, Vicineum, received a complete response letter from the Agency which put tremendous pressure on the stock. The company is eager to conduct a Type A meeting with the FDA to discuss the path ahead.
Artículo de análisis • Aug 12

Earnings Update: Here's Why Analysts Just Lifted Their Sesen Bio, Inc. (NASDAQ:SESN) Price Target To US$7.00

Investors in Sesen Bio, Inc. ( NASDAQ:SESN ) had a good week, as its shares rose 4.7% to close at US$4.04 following the...
Artículo de análisis • Feb 18

News Flash: 3 Analysts Think Sesen Bio, Inc. (NASDAQ:SESN) Earnings Are Under Threat

Today is shaping up negative for Sesen Bio, Inc. ( NASDAQ:SESN ) shareholders, with the analysts delivering a...
Artículo de análisis • Jan 26

Is Sesen Bio (NASDAQ:SESN) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. Indeed, Sesen Bio...
Artículo de análisis • Dec 21

Sesen Bio, Inc.'s (NASDAQ:SESN) Profit Outlook

With the business potentially at an important milestone, we thought we'd take a closer look at Sesen Bio, Inc.'s...

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Thomas Cannell en comparación con los beneficios de Sesen Bio?
FechaCompensación totalSalarioIngresos de la empresa
Dec 31 2022n/an/a

-US$20m

Sep 30 2022n/an/a

-US$3m

Jun 30 2022n/an/a

US$48m

Mar 31 2022n/an/a

US$54m

Dec 31 2021US$5mUS$558k

-US$336k

Sep 30 2021n/an/a

-US$24m

Jun 30 2021n/an/a

-US$118m

Mar 31 2021n/an/a

-US$119m

Dec 31 2020US$2mUS$533k

-US$23m

Sep 30 2020n/an/a

-US$41m

Jun 30 2020n/an/a

-US$32m

Mar 31 2020n/an/a

-US$60m

Dec 31 2019US$1mUS$520k

-US$107m

Sep 30 2019n/an/a

-US$81m

Jun 30 2019n/an/a

-US$82m

Mar 31 2019n/an/a

-US$36m

Dec 31 2018US$2mUS$198k

-US$34m

Compensación vs. Mercado: La compensación total ($USD4.92M) de Thomas está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD6.94M).

Compensación vs. Ingresos: La compensación de Thomas ha aumentado mientras la empresa no es rentable.

CEO

Thomas Cannell (60 yo)

4.6yrs
Permanencia
US$4,921,698
Compensación

Dr. Thomas R. Cannell, DVM, has been President, Chief Executive Officer and Director at Sesen Bio, Inc. since August 7, 2018. He served as Chief Operating Officer of Orexigen Therapeutics, Inc. since June...

Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Thomas Cannell
President4.6yrsUS$4.92m0.048%
$ 1.2m
Monica Forbes
CFO & Treasurer3.6yrsUS$1.87m0.036%
$ 926.9k
Glen MacDonald
Chief Technology Officer6.1yrsUS$1.27m0.025%
$ 645.2k
Gregory L. Verdine
Co-Founderno datasin datossin datos
Elly Ryu
Corporate Controller & Principal Accounting Officer1.9yrssin datos0.050%
$ 1.3m
Erin Clark
Vice President of Corporate Strategy & Investor Relationsno datasin datossin datos
Mark Sullivan
General Counsel3.6yrsUS$1.15m0.022%
$ 566.6k
Steve Barbera
Vice President of Market Access1.8yrssin datossin datos
David Brooks
Senior Vice President of Clinical Development5.8yrssin datossin datos
Dennis Kim
Chief Medical Officer4.3yrsUS$709.28ksin datos
Kirstin Anderson
Senior Director of Finance1.9yrssin datossin datos
Minori Rosales
Chief Development Officer1.2yrssin datossin datos
3.6yrs
Permanencia media
53yo
Promedio de edad

Equipo directivo experimentado: El equipo directivo de SESN se considera experimentado (3.6 años antigüedad media).

Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Thomas Cannell
President4.6yrsUS$4.92m0.048%
$ 1.2m
Neal Shore
Member of Medical Advisory Boardno datasin datossin datos
Jay Duker
Independent Chairman of the Board8.2yrsUS$251.28k0%
$ 0
Michael Jewett
Independent Director1.7yrsUS$469.77k0%
$ 0
Carrie Bourdow
Independent Director3.1yrsUS$215.91k0%
$ 0
Jason Keyes
Independent Director3.1yrsUS$219.01k0%
$ 0
Wassim Kassouf
Member of Medical Advisory Boardno datasin datossin datos
Rian Dickstein
Member of Medical Advisory Boardno datasin datossin datos
Thomas Keane
Member of Medical Advisory Boardno datasin datossin datos
Donald Lamm
Member of Medical Advisory Boardno datasin datossin datos
Alon Weizer
Member of Medical Advisory Boardno datasin datossin datos
Michael O'Donnell
Member of Medical Advisory Boardno datasin datossin datos
3.1yrs
Permanencia media
59.5yo
Promedio de edad

Junta con experiencia: La junta directiva de SESN se considera experimentada (3.1 años de antigüedad promedio).

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2023/03/08 23:54
Precio de las acciones al final del día2023/03/07 00:00
Beneficios2022/12/31
Ingresos anuales2022/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Sesen Bio, Inc. está cubierta por 7 analistas. 1 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
John NewmanCanaccord Genuity
Swayampakula RamakanthH.C. Wainwright & Co.
Christopher HowertonJefferies LLC